Successful experience of combined immunochemotherapy at refractory course of primary cutaneous peripheral T-cell lymphoma, unspecified
- Authors: Gorenkova L.G1, Kravchenko S.K1, Belousova I.E2,3, Babicheva L.G4, Kalashnikova D.D5, Poddubnaya I.V4
-
Affiliations:
- National Medical Research Center for Hematology
- S.M. Kirov Military Medical Academy
- Saint Petersburg Medical and Social Institute
- Russian Medical Academy of Continuous Professional Education
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 21, No 2 (2019)
- Pages: 25-28
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33506
- DOI: https://doi.org/10.26442/18151434.2019.2.190399
- ID: 33506
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Liliia G Gorenkova
National Medical Research Center for Hematology
Email: l.aitova@mail.ru
Cand. Sci. (Med.) Moscow, Russia
Sergei K Kravchenko
National Medical Research Center for Hematology
Email: kravchenko.s@blood.ru
Cand. Sci. (Med.), Assoc. Prof. Moscow, Russia
Irena E Belousova
S.M. Kirov Military Medical Academy; Saint Petersburg Medical and Social Institute
Email: irena.belousova@mail.ru
D. Sci. (Med.), Prof. Moscow, Russia
Lali G Babicheva
Russian Medical Academy of Continuous Professional Education
Email: lalibabicheva@mail.ru
Cand. Sci. (Med.), Assoc. Prof. Moscow, Russia
Daria D Kalashnikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)Student Moscow, Russia
Irina V Poddubnaya
Russian Medical Academy of Continuous Professional Education
Email: ivprectorat@inbox.ru
D. Sci. (Med.), Full Prof. Moscow, Russia
References
- Enos T.H et al. Brentuximabvedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol 2017; Report 1-6.
- Cerroni L. Skin lymphoma: the illustrated guide. Fourth edition. 2014; p. 155-62.
- Willemze R, Jaffe E.S, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
- Niitsu N, Kohori M, Higashihara M et al. Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 2007; 98 (1): 109-12.
- Truemper I, Wulf G, Ziepert M et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial. J Clin Oncol.
- Spectrum Pharmaceuticals, Inc. Phase 1 Dose Finding Study of BelinostatPlus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL). http://clinicaltrials.gov/show/NCT01839097
- Kim Y.H, Tavallaee M, Sundram U et al. Phase II investigator-initiated study of brentuximabvedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. Am Soc Clin Oncol 2015; 20: 1-9.
- Talpur R, Singh L, Daulat S et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-60.
- Pileri S.A, Ralfkiaer E, Weisenburger D.D et al. Peripheral T-cell lymphoma, not otherwise specified. In: Swerdlow S.H, Campo E, Harris N.L et al., eds. WHO Classification of Tumors of Haematopoieticamd Lymphoid Tissues. Lyon: IARC Press, 2017; p. 403-7.